Most patients with persistent pulmonary symptoms after recovering from mild to moderate COVID-19 infection have normal ...

The biotech’s phase 3 delivered the hoped-for second biomarker hit, reporting an 82% decline in serum creatine kinase after 12 months. BridgeBio’s base case and upside targets for the muscle damage ...

From rural kitchens filled with smoke to city streets choked with fumes, women face an invisible threat that fuels asthma, ...

The findings underscore the need to explore alternative therapeutic approaches to managing persistent symptoms, the authors ...

Minnesota has seen the highest jump in activity, with 17 commercial flocks, 2 backyard flocks, and almost 600,000 birds ...

PAP is a rare lung condition that can be difficult to diagnose because it may mimic many other more common lung diseases,” ...

United Therapeutics Corp. (($UTHR)) announced an update on their ongoing clinical study. United Therapeutics Corp. is conducting a study titled ...

Japanese and US researchers have developed a groundbreaking treatment for people who can’t breathe through their lungs — by ...

All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 2 open-label extension study titled ‘A ...